CompletedPhase 2

Contrast Enhanced Ultrasound for Evaluation of Reflux Nephropathy

United States10 participantsStarted 2016-03

Plain-language summary

The study will be evaluating the efficacy and safety of a contrast drug in pediatric renal ultrasound.

Who can participate

Age range8 Years – 50 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Informed consent * Age more than or equal to 8 years * Patient with history of urinary tract infection (UTI) and history of Voiding Cystourethrogram (VCUG) for vesicoureteral reflux * Candidate for Dimercaptosuccinic acid (DMSA) scan or scan for renal scar * Demonstration of renal scarring by DMSA scan or renal ultrasound without contrast Includes healthy volunteers Exclusion Criteria: * Age less than 8years * Allergy to contrast or related products * Cardiac shunt/ congenital heart anomalies * Abnormal baseline ECG * Open heart surgery * Evidence of retinopathy * Patient in intensive care * Unable to comply with study requirement * History of emphysema * Unable to maintain oxygen saturation of 92% on at room air * Pregnancy and lactation

What they're measuring

Visualization of Renal Scars Compared to Previous Imaging

Timeframe: 1 hour

Trial details

NCT IDNCT02786810

SponsorUniversity of Tennessee

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2016-11

Results submitted2017-10-24

View on ClinicalTrials.gov More Urinary Tract Infection trials